Clinical Perspective New Therapies in Resistant Hypertension

Name: Clinical Perspective on New Therapies in Resistant Hypertension
Uploaded: 2025-11-24T05:00:00+00:00
Description: From AHA 2025 in New Orleans, Dr. Clyde Yancy from Northwestern University delivers an important update on breakthrough therapies transforming the ma

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Sotagliflozin in HFpEF Without Diabetes: Inside the SOTA-P-CARDIA Trial from AHA 2025
Sotagliflozin in HFpEF Without Diabetes: Inside the SOTA-P-CARDIA Trial from AHA 2025
AHA 2025 Clinical Insights: Advancing Cardiology Care
Sotagliflozin in HFpEF Without Diabetes: Inside the SOTA-P-CARDIA Trial from AHA 2025
- Juan Badimon, PhD, FAHA
The Lp(a)-Lowering Landscape: Navigating Current and Future Therapeutic Options
The Lp(a)-Lowering Landscape: Navigating Current and Future Therapeutic Options
AHA 2025 Clinical Insights: Advancing Cardiology Care
The Lp(a)-Lowering Landscape: Navigating Current and Future Therapeutic Options
- Erin Michos
The LDL-C-Lowering Landscape: Navigating Current and Future Therapeutic Options
The LDL-C-Lowering Landscape: Navigating Current and Future Therapeutic Options
AHA 2025 Clinical Insights: Advancing Cardiology Care
The LDL-C-Lowering Landscape: Navigating Current and Future Therapeutic Options
- Prof. Kausik Ray
POLY HF Trial: A Polypill Strategy for Heart Failure With Reduced Ejection Fraction (HFrEF)
POLY HF Trial: A Polypill Strategy for Heart Failure With Reduced Ejection Fraction (HFrEF)
Heart Failure
POLY HF Trial: A Polypill Strategy for Heart Failure With Reduced Ejection Fraction (HFrEF)
- Ambarish Pandey, MD

Clinical Perspective on New Therapies in Resistant Hypertension

Recommended

Title

Share on ReachMD